KRAS inhibitors

ASCO: Bristol Myers' KRAS confirmatory data avoid Amgen's flaws but leave FDA prospect unclear
Fierce Pharma
Sun, 06/2/24 - 02:51 pm
ASCO 2024
Bristol Myers Squibb
Amgen
KRAS inhibitors
Krazati
non-small cell lung cancer
Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options
Fierce Biotech
Fri, 05/17/24 - 11:03 am
Erasca
layoffs
ERAS-4001
KRAS inhibitors
BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class
Fierce Biotech
Thu, 05/2/24 - 11:32 am
BridgeBio
funding
venture capital
KRAS inhibitors
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS
BioSpace
Fri, 04/5/24 - 11:42 am
Merck
clinical trials
KRAS inhibitors
MK-1084
non-small lung cancer
Frontier gets $80M, Galapagos’ backing to make a better KRAS drug
BioPharma Dive
Thu, 02/22/24 - 11:18 pm
Frontier Medicines
Galapagos
funding
KRAS inhibitors
Jazz buys KRAS inhibitors from Redx in $880m deal
Pharmaphorum
Wed, 02/7/24 - 11:18 am
Jazz Pharma
Redx Pharma
KRAS inhibitors
oncology
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Mon, 10/23/23 - 10:30 am
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Amgen
Lumakras
FDA
KRAS inhibitors
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Fierce Pharma
Thu, 10/5/23 - 09:10 pm
Mirati Therapeutics
Sanofi
M&A
KRAS inhibitors
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
BioSpace
Thu, 08/24/23 - 11:50 am
Roche
Genentech
divarasib
KRAS inhibitors
solid tumors
clinical trials
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Mon, 08/21/23 - 06:56 pm
Amgen
Lumakras
KRAS inhibitors
FDA
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Wed, 08/9/23 - 11:55 am
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
Pharma Voice
Tue, 07/25/23 - 10:07 am
Affini-T Therapeutics
oncology
KRAS inhibitors
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
Fierce Biotech
Tue, 04/18/23 - 10:18 pm
Eli Lilly
Amgen
Mirati Therapeutics
KRAS inhibitors
AACR
ESMO 2022 movers – KRAS backfires
EP Vantage
Thu, 09/15/22 - 10:12 am
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames
Fierce Pharma
Sun, 09/11/22 - 11:07 pm
Amgen
lung cancer
ESMO
KRAS inhibitors
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Fierce Biotech
Mon, 12/14/20 - 11:07 am
Genentech
Relay Therapeutics
Roche
KRAS inhibitors
Eli Lilly crashes out of KRAS race as toxicity sees it ditch phase 1 effort
Fierce Biotech
Thu, 07/30/20 - 11:11 am
Eli Lilly
KRAS inhibitors
cancer
Researchers Develop New Class of Lung Cancer Drugs
BioSpace
Thu, 09/19/19 - 12:15 pm
lung cancer
KRAS inhibitors
Institute of Cancer Research
drug development
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Sat, 09/7/19 - 06:38 pm
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis

Pages